Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
INMUNO-K
- Development stage
- Preclinical
- Lead developer
- Laboratorios Farmalan
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
INMUNO-K is an investigational immunomodulatory formulation based on calcifediol (25-hydroxyvitamin D3), currently under development by Laboratorios Farmalan, a subsidiary of Faes Farma. The project is focused on utilizing the immunomodulatory properties of vitamin D analogues to treat autoimmune diseases and other conditions requiring immune system modulation. By targeting the Vitamin D Receptor (VDR), the formulation aims to regulate immune responses that are typically dysregulated in autoimmune pathologies. It is part of a broader R&D effort by Faes Farma to expand the therapeutic applications of calcifediol beyond traditional bone health and vitamin D deficiency.
- Other names
- immunomodulatory calcifediol formulation project
Beyond the preview
Go deeper on INMUNO-K.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on INMUNO-K.